OBJECTIVE： To observe clinical efficacy and safety of linezolid combined with teicoplanin in the treatment of severe methicillin-resistant Staphylococcus aureus （MRSA） pneumonia. METHODS： 150 patients diagnosed as severe MRSA pneumonia were collected and divided into combination group， linezolid group and teicoplanin group， with 50 cases in each group occording to random number table. Linezolid group received Linezolid injection 600 mg， ivgtt， bid； teicoplanin group received Teicoplanin for injection 400 mg， ivgtt， bid； combination group received Linezolid injection with same usage and dosage， for 1 week， and then received Teicoplanin injection with same usage and dosage， for 1 week. All 3 groups received treatment for 2 weeks. The clinical effective rate， effective bacterial clearance rate， serum levels of serum inflammatory factors [CRP， PCT， TNF-α] and leucocyte count were observed in 3 groups， and the occurrence of ADR were compared among 3 groups. RESULTS： The clinical effective rates of combination group and linezolid group were 90.0％ and 84.0％， and effective bacterial clearance rates were 86.0％ and 80.0％， which were significantly higher than those of teicoplanin group （70.0％ and 64.0％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in serum inflammatory factors and leucocyte count among 3 groups （P＞0.05）. After treatment， the levels of CRP， PCT， TNF-α and leukocyte in 3 groups were decreased significantly， and the combination group and linezolid group were significantly lower than the teicoplanin group， with statistical significance （P＜0.05）. The incidence of ADR in combination group were significantly lower than in linezolid group and teicoplanin group， with statistical significance （P＜0.05）. CONCLUSIONS： Linezolid combined with teicoplanin is similar to linezolid alone in the treatment of severe MRSA pneumonia. Both can improve the levels of serum inflammatory factors and leucocyte count， and combination group and linezolid group were superior to teicoplanin group， while patients in combination group show low incidence of adverse reactions， with higher safety.